WebJul 29, 2024 · The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2024 Q2 earnings call. Seeking Alpha - Go to Homepage Entering text into the input field will ... Web2 GAAP and non-GAAP earnings per share include the net impact of ($0.24) from Acquired IPRD and licensing income incurred year-to-date 2024. "I am very pleased with continued strong demand for our in-line products and new product portfolio, resulting in solid top …
Bristol-Myers Squibb Co. Analysis of Profitability Ratios (Q)
WebJul 28, 2024 · Bristol Myers Squibb (BMS) has reported a 2% rise in revenues to $11.9bn in the second quarter (Q2) of 2024 compared to $11.7bn in Q2 last year.. The revenue growth was driven by in-line products, mainly Eliquis and Opdivo, as well as the company’s latest product portfolio comprising Abecma, Opdualag and Reblozyl. WebJul 19, 2024 · BMS’ Q2 2024 adjusted earnings per share is expected to be $1.86 per Trefis analysis, slightly above the consensus estimate of $1.83. The company’s adjusted … mickle print wincheap
Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings …
WebOct 21, 2024 · BMS’ Q2 2024 adjusted earnings per share is expected to be $1.85 per Trefis analysis, slightly above the consensus estimate of $1.82. This compares with the $2.00 figure reported in the prior ... WebForward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those … WebJul 28, 2024 · Tim Power. Vice President, Head of Investor Relations at Bristol-Myers Squibb. Thanks, Kathryn, and good morning, everybody. Thanks for joining us this morning for our second quarter 2024 earnings call. Joining me this morning with prepared remarks are Giovanni Caforio, our Board Chair and Chief Executive Officer; and David Elkins, our … mickle trafford cattery